PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 2 6 2001

In re Application of:

Havenga et al.

Serial No.: 09/348,354

Filed: July 7, 1999

For: CHIMAERIC ADENOVIRUSES

Examiner: G. Lee

Group Art Unit: 1633

Attorney Docket No.: 4123US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 2021

rson having reasonable basis to expect mailing occur on date of deposit shown pursuant to 37

Lynette Eliason
Typed/printed name of person whose signature is contained above

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Second Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Second Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

DOCUMENTS

U.S. Patent Documents

U.S. Patent No.	Issue Date	Inventor
4,487,829	12/11/1984	Sharp et al.
4,517,686	05/21/1985	Ruoslahti et al.
4,578,079	03/25/1986	Ruoslahti et al.
4,589,881	05/20/1986	Pierschbacher et al.
4,593,002	06/03/1986	Dulbecco
4,792,525	12/20/1988	Ruoslahti et al.
4,797,368	01/10/1989	Carter et al.
4,956,281	09/11/1990	Wallner et al.
5,024,939	06/18/1991	Gorman
5,096,815	03/17/1992	Ladner et al.
5,166,320	11/24/1992	Wu et al.
5,198,346	03/30/1993	Ladner et al.
5,204,445	04/20/1993	Plow et al.
5,223,394	06/29/1993	Wallner
5,223,409	06/29/1993	Ladner et al.
5,240,846	08/31/1993	Collins et al.
5,246,921	09/21/1993	Reddy et al.
5,332,567	07/26/1994	Goldenberg
5,349,053	09/20/1994	Landolfi
5,403,484	04/04/1995	Ladner et al.
5,436,146	07/25/1995	Shenk et al.
5,443,953	08/22/1995	Hansen et al.
5,474,935	12/12/1995	Chatterjee et al.

PCT

U.S.	Patent Documents

U.S. Patent No.	Issue Date	Inventor
5,521,291	05/28/1996	Curiel et al.
5,534,423	07/09/1996	Palsson et al.
5,543,328	08/06/1996	McClelland et al.
5,547,932	08/20/1996	Curiel et al.
5,552,311	09/03/1996	Sorscher et al.
5,559,099	09/24/1996	Wickham et al.
5,571,698	11/05/1996	Ladner et al.
5,622,699	04/22/1997	Ruoslahti et al.
5,712,136	01/27/1998	Wickham et al.
5,731,190	03/24/1998	Wickham et al.
5,756,086	05/26/1998	McClelland et al.
5,770,442	06/23/1998	Wickham et al.
5,922,315	07/13/1999	Roy
	Foreign Patent Documents	
Document No.	<u>Date</u>	Country
259212	03/09/1988	EP
2078631	03/19/1990	ЛР
WO 91/00360	01/10/1991	PCT
WO 91/05805	05/02/1991	PCT
WO 91/05871	05/02/1991	PCT
WO 92/02553	02/20/1992	PCT
WO 92/13081	08/06/1992	PCT
WO 93/03769	03/04/1993	PCT

04/01/1993

WO 93/06223

Foreign Patent Documents

Document No.	<u>Date</u>	Country
WO 93/07282	04/15/1993	PCT
WO 93/07283	04/15/1993	PCT
WO 94/08026	04/14/1994	PCT
WO 94/10323	05/11/1994	PCT
WO 94/11506	05/26/1994	PCT
WO 94/15644	07/21/1994	PCT
WO 94/17832	08/14/1994	PCT
WO 94/24299	10/27/1994	PCT
WO 94/26915	11/24/1994	PCT
WO 95/05201	02/23/1995	PCT
WO 95/06745	03/09/1995	PCT
WO 95/14785	06/01/1995	PCT
WO 95/16037	06/15/1995	PCT
WO 95/21259	08/10/1995	PCT
WO 95/26412	10/05/1995	PCT
WO 95/27071	10/12/1995	PCT
WO 95/31187	11/23/1995	PCT
WO 95/31566	11/23/1995	PCT
WO 96/00790	01/11/1996	PCT
WO 96/07739	03/14/1996	PCT
WO 96/10087	04/04/1996	PCT
WO 96/13597	05/09/1996	PCT
WO 96/14837	05/23/1996	PCT
WO 96/17073	06/06/1996	PCT

Foreign Patent Documents

Document No.	<u>Date</u>	Country
WO 96/18740	06/20/1996	PCT
WO 97/24453	07/10/1997	PCT
WO 97/38723	10/23/1997	PCT
WO 98/07865	02/26/1998	PCT
WO 98/11221	03/19/1998	PCT
WO 98/13499	04/02/1998	PCT
WO 98/22609	05/28/1998	PCT
WO 98/32842	07/30/1998	PCT
WO 98/40509	09/17/1998	PCT

Other Documents

- Albiges-Rizo et al., <u>Human Adenovirus Serotype 3 Fiber Protein</u>, Journal of Biological Chemistry, 266(6), 3961-3967 (1991).
- Bai et al., Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2
 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells, Journal of Virology, 67(9), 5198-5205 (1993).
- Bailey et al., <u>Phylogenetic Relationships among Adenovirus Serotypes</u>, Virology, 205, 439-452 (1994).
- Ball-Goodrich et al., <u>Parvoviral Target Cell Specificity</u>: <u>Acquisition of Fibrotropism by a Mutant of the Lymphotropic Strain of Minute Virus of Mice Involves Multiple Amino Acid Substitutions within the Capsid</u>, Virology, 184, 175-186 (1991).
- Batra et al., <u>Receptor-mediated gene delivery employing lectin-binding specificity</u>, Gene Therapy, 1, 255-260 (1994).
- Boursnell et al., <u>In vitro construction of a recombinant adenovirus Ad2:Ad5</u>, Gene, 13, 311-317 (1981).

- Caillet-Boudin et al., <u>Functional and Structural Effects of an Ala to Val Mutation in the Adenovirus Serotype 2 Fibre</u>, J. Mol. Biol., 217, 477-486 (1991).
- Chroboczek et al., <u>The Sequence of the Genome of Adenovirus Type 5 and Its Comparison with</u> the Genome of Adenovirus Type 2, Virology, 186, 280-285 (1992).
- Cotten et al., <u>High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles, Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992).</u>
- Cotten et al., <u>Transferrin-polycation-mediated introduction of DNA into human leukemic cells:</u>
 <u>Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels</u>, Proc. Natl. Acad. Sci. USA, 87, 4033-4037 (1990).
- Crawford-Miksza et al., <u>Adenovirus Serotype Evolution Is Driven by Illegitimate Recombination in the Hypervariable Regions of the Hexon Protein</u>, Virology, 224, 357-367 (1996).
- Crawford-Miksza et al., <u>Analysis of 15 Adenovirus Hexon Proteins Reveals the Location and Structure of Seven Hypervariable Regions Containing Serotype-Specific Residues</u>, J. Virol., 70(3), 1836-1844 (1996).
- Crompton et al., Expression of a foreign epitope on the surface of the adenovirus hexon, J. Gen. Virol., 75(1), 133-139 (1994).
- Crystal, Ronald G., <u>Transfer of Genes to Humans: Early Lessons and Obstacles to Success</u>, Science, 270, 404-410 (1995).
- Curiel et al., <u>Adenovirus enhancement of transferrin-polylysine-mediated gene delivery</u>, Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991).
- Curiel et al., <u>High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes</u>, Human Gene Therapy, 3, 147-154 (1992).
- Defer et al., <u>Human Adenovirus-Host Cell Interactions: Comparative Study with Members of Subgroups B and C</u>, Journal of Virology, 64(8), 3661-3673 (1990).
- Dupuit et al., <u>Regenerating Cells in Human Airway Surface Epithelium Represent Preferential Targets for Recombinant Adenovirus</u>, Human Gene Therapy, 6, 1185-1193 (1995).
- Etienne-Julan et al., The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker, Journal of General Virology, 73, 3251-3255 (1992).

- Falgout et al., <u>Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene</u>, Journal of Virology, 62(2), 622-625 (1988).
- Greber et al., <u>Stepwise Dismantling of Adenovirus 2 during Entry into Cells</u>, Cell, 75, 477-486 (1993).
- Green et al., Evidence for a repeating cross-β sheet structure in the adenovirus fibre, EMBO Journal, 2(8), 1357-1365 (1983).
- Grubb et al., <u>Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans</u>, Nature, 371, 802-806 (1994).
- Han et al., <u>Ligand-directed retroviral targeting of human breast cancer cells</u>, Proc. Natl. Acad. Sci. USA, 92, 9747-9751 (1995).
- Henry et al., <u>Characterization of the Knob Domain of the Adenovirus Type 5 Fiber Protein</u>
 <u>Expressed in Escherichia coli</u>, Journal of Virology, 68(8), 5239-5246 (1994).
- Hong et al., The Amino Terminus of the Adenovirus Fiber Protein Encodes the Nuclear Localization Signal, Virology, 185(2), 758-767 (1991).
- Horvath et al., Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection, Journal of Virology, 62(1), 341-345 (1988).
- Huang et al., <u>Upregulation of Integrins ανβ3 and ανβ5 on Human Monocytes and T Lymphocytes Facilitates Adenovirus-Mediated Gene Delivery</u>, Journal of Virology, 69(4), 2257-2263 (1995).
- Karayan et al., Oligomerization of Recombinant Penton Base of Adenovirus Type 2 and Its Assembly with Fiber in Baculovirus-Infected Cells, Virology, 202, 782-795 (1994).
- Kass-Eisler et al., Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo, Proc. Natl. Acad. Sci. USA, 90, 11498-11502 (1993).
- Komoriya et al., <u>The Minimal Essential Sequence for a Major Cell Type-specific Adhesion Site</u>
 (CS1) within the Alternatively Spliced Type III Connecting Segment Domain of
 Fibronectin Is Leucine-Aspartic Acid-Valine, Journal of Biological Chemistry, 266(23),
 15075-15079 (1991).
- Maraveyas et al., <u>Targeted Immunotherapy An update with special emphasis on ovarian cancer</u>, Acta Oncologica, 32(7/8), 741-746 (1993).

- Mastrangeli et al., *In Vivo* Gene Transfer to the Lung of Experimental Animals Using a Chimeric Ad5/Ad7 Adenovirus Vector, Ped. Pulm., Suppl., 12, 230, Abst. No. 180 (1995).
- Mastrangeli et al., "Sero-Switch" Adenovirus-Mediated In Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype, Human Gene Therapy, 7, 79-87 (1996).
- Mathias et al., <u>Multiple Adenovirus Serotypes Use αν Integrins for Infection</u>, Journal of Virology, 68(10), 6811-6814 (1994).
- Mautner et al., <u>Recombination in Adenovirus: Analysis of Crossover Sites in Intertypic Overlap</u> <u>Recombinants</u>, Virology, 139, 43-52, (1984).
- Mautner et al., Recombination in Adenovirus: DNA Sequence Analysis of Crossover Sites in Intertypic Recombinants, Virology, 131, 1-10 (1983).
- Michael et al., Addition of a short peptide ligand to the adenovirus fiber protein, Gene Therapy, 2, 660-668 (1995).
- Michael et al., <u>Binding-incompetent Adenovirus Facilitates Molecular Conjugate-mediated Gene</u>

 <u>Transfer by the Receptor-mediated Endocytosis Pathway</u>, Journal of Biological Chemistry, 268(10), 6866-6869 (1993).
- Miller et al., Targeted vectors for gene therapy, FASEB Journal, 9, 190-199 (1995).
- Neda et al., <u>Chemical Modification of an Ecotropic Murine Leukemia Virus Results in</u>
 <u>Redirection of Its Target Cell Specificity</u>, Journal of Biological Chemistry, 266(22), 14143-14146 (1991).
- Nemerow et al., Adenovirus entry into host cells: a role for α_v integrins, Trends In Cell Biology, 4, 52-55 (1994).
- Nemerow et al., <u>The Role of αν Integrins in Adenovirus Infection</u>, Biology of Vitronectins and their Receptors, 177-184 (1993).
- Novelli et al., <u>Deletion Analysis of Functional Domains in Baculovirus-Expressed Adenovirus</u>

 <u>Type 2 Fiber</u>, Virology, 185, 365-376 (1991).
- Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, (1995), file:///F|/NIHrec.htm 1/4/01 1:37 pm.

- Peteranderl et al., <u>Trimerization of the Heat Shock Transcription Factor by a Triple-Stranded</u> α-Helical Coiled-Coil, Biochemistry, 31, 12272-12276 (1992).
- Pring-Åkerblom et al., <u>Sequence Characterization and Comparison of Human Adenovirus</u>
 <u>Subgenus B and E Hexons</u>, Virology, 212, 232-36 (1995).
- Roberts et al., <u>Three-Dimensional Structure of the Adenovirus Major Coat Protein Hexon</u>, Science, 232, 1148-51 (1986).
- Russell et al., <u>Retroviral vectors displaying functional antibody fragments</u>, Nucleic Acids Research, 21(5), 1081-1085 (1993).
- Signäs et al., <u>Adenovirus 3 Fiber Polypeptide Gene: Implications for the Structure of the Fiber Protein</u>, Journal of Virology, 53(2), 672-678 (1985).
- Silver et al., <u>Interaction of Human Adenovirus Serotype 2 with Human Lymphoid Cells</u>, Virology, 165, 377-387 (1988).
- Stewart et al., <u>Difference imaging of adenovirus</u>: bridging the resolution gap between X-ray crystallography and electron microscopy, EMBO Journal, 12(7), 2589-2599 (1993).
- Verma et al., Gene Therapy promises, problems and prospects, Nature, 389, 239-42 (1997).
- Wadell, G., Molecular Epidemiology of Human Adenoviruses, Curr. Top. Microbiol. Immunol., 110, 191-220 (1984).
- Wagner et al., Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes, Proc. Natl. Acad. Sci. USA, 89, 6099-6103 (1992).
- Watson et al., An Antigenic Analysis of the Adenovirus Type 2 Fibre Polypeptide, Journal of Virology, 69, 525-535 (1988).
- Wickham et al., Integrins $\alpha_{\nu}\beta_{3}$ and $\alpha_{\nu}\beta_{5}$ Promote Adenovirus Internalization but Not Virus Attachment, Cell, 73, 309-319 (1993).
- Wickham et al., <u>Integrin ανβ5 Selectively Promotes Adenovirus Mediated Cell Membrane</u> <u>Permeabilization</u>, Journal of Cell Biology, 127(1), 257-264 (1994).
- Chu et al., Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins, Gene Therapy, 1, 292-299 (1994).

ų i

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Second Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits. I hereby certify that no item of information contained in the Second Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Allen C. Turner

Registration No. 33,041 Attorney for Applicants

TRASKBRITT

P. O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: (801) 532-1922

Date: January 24, 2001

ACT/jml

Enclosures: Form PTO-1449

Copy of documents cited

N:\2183\4123\IDS (2d supp).wpd

Form PTO-1		01	PEVC	Docket Number (Optional) 4123US Application Number 09/348,354				er .
INFORM		CLOSURF CITA LICATION _{JAN}		Applicant	lavenga et	al.		
	(Use several she	ets if necessory)	* OFFIL	100	, 1999	Group Art	: Unit 10	633
,		U.S.	PATENT	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DA	
	4,487,829	12/11/1984	s	harp et al.				
	4,517,686	05/21/1985	Rue	oslahti et al.				
	4,578,079	03/25/1986	Ruc	oslahti et al.		<u> </u>		
	4,589,881	05/20/1986	Pierso	chbacher et al.				
		FOREIG	N PATEN	T DOCUMENTS				
					5 , 100	0.1001.100	Trans	slation
	DOCUMENT NUMBER	DATE	<u> </u>	COUNTRY	CLASS	SUBCLASS	YES	NO
	259212	03/09/1988		EP				
	2078631	03/19/1990		JP				
	WO 91/00360	01/10/1991		PCT		<u> </u>		
	WO 91/05805	05/02/1991		PCT		<u> </u>		
	WO 91/05871	05/02/1991		PCT			•	
		O	THER DO	CUMENTS	(Including A	uthor, Title, Date	, Pertinent P	'ages, Etc.)
-		s-Rizo et al., <u>Huma</u> stry, 266(6), 3961		us Serotype 3 Fiber f 1).	<u>Protein</u> , Jou	ırnal of Biol	ogical	
	Penton		lish Its Cell-I	rg-Gly-Asp (RGD) Se Rounding Activity ar 98-5205 (1993).				
	1 1	et al., <u>Phylogenetic</u> 32 (1994).	c Relationsh	ips among Adenovir	us Serotype	es, Virology	, 205,	
	of the	Lymphotropic Stra	in of Minute	t Cell Specificity: Ac Virus of Mice Invol logy, 184, 175-186	ves Multipl			<u>Viutant</u>
		t al., <u>Receptor-me</u> y, 1, 255-260 (19		delivery employing	lectin-bindii	ng specificit	<u>y</u> , Gene	
		ell et al., <u>In vitro c</u> 7 (1981).	onstruction	of a recombinant ad	lenovirus A	<u>d2:Ad5</u> , Ge	ne, 13,	
				Structural Effects of Biol., 217, 477-486		/al Mutatior	in the	
EXAMINER				DATE CONSIDERE	D			
				on is in conformance by of this form with n				

Form PTO-1			6	IPE ve	Docket Number (Optional) Application Number 4123US 09/348,354				
INFORM	IN A	AN APPLI	.1001	TION 2 6 2001	Applicant	Havenga et	al.		
	(Use s	everal sheets	if necessar	at o	Filing Date July 7	7, 1999	Group Art	t Unit 10	633
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		OCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DA	
	4,5	593,002	06/03/1986		Dulbecco				
	4,7	92,525	12/20/1988	Ru	oslahti et al.				
	4,7	797,368	01/10/1989	С	arter et al.				
	4,9	956,281	09/11/1990	w	allner et al.				
			FOREIG	N PATEN	T DOCUMENTS				
	- 22104		2.475			31.456	CUIDOL A SS	Tran	slation
	DOCUMENT NUMBER		DATE		COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 9	2/02553	02/20/1992	<u> </u>	PCT			<u> </u>	
	WO 9	2/13081	08/06/1992		PCT	 		<u> </u>	<u> </u>
	WO 9	3/03769	03/04/1993	<u> </u>	PCT	<u> </u>		<u> </u>	
	WO 93/06223		04/01/1993		PCT	 		<u> </u>	<u> </u>
	WO 9	3/07282	04/15/1993		PCT			'	
			0	THER DO	CUMENTS	(Including A	outhor, Title, Date	, Pertinent P	ages, Etc.)
					the Genome of Ader e 2, Virology, 186,			<u>Compari</u>	ison
		construct	ts using the endo	osome-disru	or-mediated delivery option activity of def d. Sci. USA, 89, 60	ective or ch	nemically in		
		Cotten et	t al., <u>Transferrin</u> on by agents tha	-polycation- at affect the	mediated introduction survival of transfection USA, 87, 4033-40	on of DNA i	into human r modulate t		
					Serotype Evolution Is Regions of the Hexo				367
		Structure		rvariable Rec	5 Adenovirus Hexo gions Containing Se				
			n et al., <u>Expressi</u> ol., 75(1), 133-1		eign epitope on the s	surface of th	ne adenovir	us hexor	<u>ı,</u> J.
		1	Ronald G., <u>Trans</u> 270, 404-410 (*		s to Humans: Early I	_essons and	l Obstacles	to Succe	ess,
EXAMINER					DATE CONSIDERE	D			
					on is in conformance by of this form with r				

Sheet 3 of 9 Application Number Docket Number (Optional) Form PTO-1449 4123US 09/348,354 INFORMATION DISCLOSURE/CITATION Applicant Havenga et al. IN AN APPLICATION JAN 2 6 2001 (Use several sheets if necessary Filing Date July 7, 1999 Group Art Unit 1633 U.S. PATENT DOCUMENTS FILING DATE **EXAMINER** DOCUMENT SUBCLASS DATE CLASS NAME INITIAL NUMBER IF APPROPRIATE 06/18/1991 5,024,939 Gorman 5,096,815 03/17/1992 Ladner et al. 5,166,320 11/24/1992 Wu et al. 03/30/1993 5,198,346 Ladner et al. FOREIGN PATENT DOCUMENTS Translation DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES NO WO 93/07283 04/15/1993 PCT WO 94/08026 04/14/1994 **PCT** WO 94/10323 05/11/1994 PCT WO 94/11506 05/26/1994 PCT WO 94/15644 07/21/1994 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Curiel et al., Adenovirus enhancement of transferrin-polylysine-mediated gene delivery, Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991). Curiel et al., High-Efficiency Gene Transfer Mediated by Adenovirus Coupled to DNA-Polylysine Complexes, Human Gene Therapy, 3, 147-154 (1992). Defer et al., Human Adenovirus-Host Cell Interactions: Comparative Study with Members of Subgroups B and C, Journal of Virology, 64(8), 3661-3673 (1990). Dupuit et al., Regenerating Cells in Human Airway Surface Epithelium Represent Preferential Targets for Recombinant Adenovirus, Human Gene Therapy, 6, 1185-1193 (1995). Etienne-Julan et al., The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker, Journal of General Virology, 73, 3251-3255 (1992). Falgout et al., Characterization of Adenovirus Particles Made by Deletion Mutants Lacking the Fiber Gene, Journal of Virology, 62(2), 622-625 (1988). Greber et al., Stepwise Dismantling of Adenovirus 2 during Entry into Cells, Cell, 75, 477-486 (1993). DATE CONSIDERED **EXAMINER** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through

citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

								561 4 01
Form PTO-		QIF	TION TION	Docket Number (Optional) Application Number 4123US 09/348,354			er	
INFOR	MATION DISCL IN AN APPL	ICATION	Je Soul	Applicant	Havenga et	al.		
	(Use several sheets	if necessary)		Filing Date July	7, 1999	Group An	t Unit 1	633
	<u></u>	U.S.	PATENT	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	5,204,445	04/20/1993	F	Plow et al.				
	5,223,394	06/29/1993		Wallner				
	5,223,409	06/29/1993	La	adner et al.				
	5,240,846	08/31/1993	С	ollins et al.				
		FOREIG	N PATEN	T DOCUMENTS	5			
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	CURCI ACC	Trans	slation
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 94/17832	08/14/1994		PCT				
	WO 94/24299	10/27/1994	_	PCT		1		
	WO 94/26915	11/24/1994		PCT				
	WO 95/05201	02/23/1995		PCT				
	WO 95/06745	03/09/1995		PCT	_		İ	
		0	THER DO	CUMENTS	(Including A	uthor, Title, Date	e, Pertinent F	ages, Etc.)
		al., <u>Evidence for</u> 2(8), 1357-1365		ı cross-β sheet stru	icture in the	<u>adenovirus</u>	fibre, EN	ИВО
		al., <u>Inefficient g</u> and humans, Nat		by adenovirus vec 02-806 (1994).	ctor to cystic	fibrosis air	way epit	helia
		., <u>Ligand-directe</u> , 92, 9747-975		targeting of human	breast canc	<u>er cells</u> , Pro	oc. Natl.	Acad.
				Knob Domain of th I of Virology, 68(8)			ber Prote	<u>ein</u>
				the Adenovirus Fib 758-767 (1991).	er Protein En	codes the I	<u>Nuclear</u>	
				ıman Peripheral Blo 1), 341-345 (1988)		ytes to Ade	enovirus	Туре
	T Lymph			s ανβ3 and ανβ5 os-Mediated Gene D				4),
EXAMINER				DATE CONSIDER	ED			
				on is in conformanc				
			•					

Form PTO-	1449	6	PE	Docket Number (Op	tional)	Application		er <u>5 07 :</u>
	MATION DÍSCL	OSURE/CITA	TION	4123US		09/348,3		
	IN AN APPL	ICATION JAN	Applicant	Havenga et	al.			
	(Use several sheets	if necessar	THE MARKO	Filing Date July	7, 1999	Group Art	Unit 1	633
		U.S.	PATENT I	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DA	
-	5,246,921	09/21/1993	Re	eddy et al.				
	5,332,567	07/26/1994	G	oldenberg				
	5,349,053	09/20/1994		Landolfi				
	5,403,484	04/04/1995	La	idner et al.				
		FOREIG	N PATEN	T DOCUMENTS	S			
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Trans	slation
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	ИО
	WO 95/14785	06/01/1995		PCT				
	WO 95/16037	06/15/1995		PCT				
	WO 95/21259	08/10/1995	PCT					
	WO 95/26412	10/05/1995		PCT				
	WO 95/27071	10/12/1995		PCT				
		0	THER DO	CUMENTS	(Including A	uthor, Title, Date	, Pertinent F	ages, Etc.)
				combinant Penton Ifected Cells, Virol				<u>lts</u>
				nination of adenov Proc. Natl. Acad.				
,	(CS1) wi	thin the Alternat	ively Spliced	al Sequence for a I I Type III Connecti of Biological Chei	ing Segment	Domain of	Fibronec	
		as et al., <u>Targete</u> Acta Oncologica,		erapy - An update 1-746 (1993).	e with specia	l emphasis	on ovari	an
				sfer to the Lung of r, Ped. Pulm., Sup				95).
	of Anti-A	denovirus Humo	ral Immune	enovirus-Mediated Defenses Against novirus Serotype, H	Repeat Aden	ovirus Vect	or	ention
EXAMINER				DATE CONSIDER	ED			
	Initial if citation con in conformance and							

Form PTO-	1449 MATION DISCI	TION S	Docket Number (Optional) 4123US Application Number 09/348,354				er <u>7 61</u>		
""	IN AN APPL	ICATION	2 6 2001	Applicant	Havenga et	al.			
	(Use several sheet	s if necessary)	- 4 5001	Filing Date July	7, 1999	Group Ar	t Unit 1	633	
		U.S.	PANTENT	DOCUMENTS				_	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	CLASS SUBCLASS		FILING DATE IF APPROPRIATE	
	5,534,423	07/09/1996	Pa	lsson et al.					
	5,543,328	08/06/1996	Mc	Clelland et al.					
	5,547,932	08/20/1996		Curiel et al.					
	5,552,311	09/03/1996	So	rscher et al.					
	_	FOREIG	ON PATEN	T DOCUMENTS	S				
	DOCUMENT NUMBER	DATÉ		COUNTRY	CLASS	SUBCLASS		slation	
	WO 96/13597 05/09/1996			PCT		<u> </u>	YES	NO	
	WO 96/13397	05/09/1996		PCT					
	WO 96/17073	06/06/1996		PCT		1			
	WO 96/18740				i.				
	WO 97/24453	07/10/1997		PCT					
		0	THER DO	CUMENTS	(Including A	Author, Title, Date	e, Pertinent F	Pages, Etc.)	
		v et al., <u>Adenovi</u> 4, 52-55 (1994)		to host cells: a role	for α _v integ	<u>rins</u> , Trends	s In Cell		
		w et al., <u>The Role</u> ceptors, 177-184		grins in Adenovirus	Infection, B	iology of Vi	tronectir	ns and	
		t al., <u>Deletion Ar</u> Fiber, Virology, 1		inctional Domains i 6 (1991).	n Baculoviru	ıs-Expressed	d Adenov	<u>virus</u>	
				ations of the Panel file:///F /NIHrec.htr			stment i	<u>n</u>	
				e Heat Shock Tran 31, 12272-12276 (ctor by a Tri	iple-Stra	<u>nded</u>	
				racterization and C 212, 232-36 (199		of Human A	denoviru	<u>s</u>	
		et al., <u>Three-Dim</u> 232, 1148-51 (ucture of the Aden	novirus Majo	r Coat Prote	ein Hexo	<u>n</u> ,	
EXAMINER				DATE CONSIDER	ED				
				on is in conformanc					

Sheet 6 of 9

Form PTO-1		<u></u>	SIPE	Docket Number (Opti	ional)	Application Number 09/348,354		
INFOR	MATION DISCLO IN AN APPLI	ICATION	TION 5	Applicant	Havenga et a	al.		
	(Use several sheets	10		Filing Date July 7	, 1999	Group Art	Unit 16	33
		U.S.	PARTENT	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DA	
	5,436,146	07/25/1995	s	Shenk et al.				
	5,443,953	08/22/1995	H	ansen et al.	Ţ			
	5,474,935	12/12/1995	Cha	atterjee et al.				
	5,521,291	05/28/1996	С	Curiel et al.	_			<u></u>
		FOREIC	N PATÉN	IT DOCUMENTS	; 			
DOCUMENT NUMBER DATE				COUNTRY	CLASS	SUBCLASS	Trans	nslation
					1		YES	NO
	WO 95/31187	11/23/1995		PCT			ļ'	ļ!
	WO 95/31566	11/23/1995		PCT	-	 		
	WO 96/00790	01/11/1996	 	PCT				
	WO 96/07739	03/14/1996		PCT		 		
-	WO 96/10087	04/04/1996	-::== >0	PCT				
		U	THEK DO	CUMENTS	(Including A	uthor, Title, Date	, Pertinent P	'ages, Etc.)
		et al., <u>Multiple A</u> , 68(10), 6811-6		Serotypes Use αν In).	tegrins for l	<u>nfection</u> , Jo	urnal of	
				enovirus: Analysis o 9, 43-52, (1984).	f Crossover	Sites in Int	ertypic	
				enovirus: DNA Sequ 31, 1-10 (1983).	ence Analys	sis of Cross	over Site	es in
		et al., <u>Addition o</u> . 2, 660-668 (19		eptide ligand to the a	adenovirus f	iber protein	, Gene	
	Gene Tra		ceptor-media	Adenovirus Facilitate ated Endocytosis Pa 193).				<u>id</u>
	Miller et	al., <u>Targeted vec</u>	ctors for ger	ne therapy, FASEB .	Journal, 9, 1	190-199 (19	995).	
	Redirection			f an Ecotropic Murin city, Journal of Biolo				
EXAMINER				DATE CONSIDERE	:D			
		-		ion is in conformance				-

Sheet 8 of 9

Form PTO-		OIPE	Docket Number (Optional) 4123US Application Number 09/348,354			er		
INFORI	MATION DISCL IN AN APPLI	TION '	Applicant Havenga et al.					
	(Use several sheets	if necessary		iling Date July 7	, 1999	Group An	t Unit 1	633
		U.S.	PACETENT?	DOCUMENTS				
EXAMINER INITIAL	DOCUMENT DATE NAME CLASS			CLASS	SUBCLASS FILING DATE IF APPROPRIATE			
	5,559,099 09/24/1996			ckham et al.				_
	5,571,698	11/05/1996	La	adner et al.				
	5,622,699	04/22/1997	Ru	oslahti et al.				
	5,712,136	01/27/1998	Wi	ckham et al.				
		FOREIG	N PATEN	T DOCUMENTS	<u> </u>			
	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Tran:	slation
	WO 97/38723	10/23/1997		PCT			125	
	WO 98/07865	02/26/1998		PCT				
	WO 98/11221	03/19/1998		PCT				
	WO 98/13499	04/02/1998		PCT				
)	WO 98/22609	05/28/1998		PCT				
		0	THER DO	CUMENTS	(Including A	uthor, Title, Date	e, Pertinent F	'ages, Etc.)
		t al., <u>Retroviral v</u> , 21(5), 1081-1		aying functional ant	ibody fragn	nents, Nucl	eic Acids	.
		t al., <u>Adenovirus</u> Journal of Virolo		ypeptide Gene: Impli 372-678 (1985).	cations for	the Structu	ire of the	<u> Fiber</u>
		al., <u>Interaction o</u> 165, 377-387		denovirus Serotype 2	with Hum	an Lympho	id Cells,	
	Stewart o	et al., <u>Difference</u> graphy and elect	imaging of	adenovirus: bridging opy, EMBO Journal,	the resolu 12(7), 258	tion gap be 19-2599 (19	tween X 993).	<u>-ray</u>
	Verma et (1997).	al., <u>Gene Thera</u>	py – promis	es, problems and pro	ospects, Na	nture, 389,	239-42	
		6., <u>Molecular Ep</u> i I-220 (1984).	demiology o	of Human Adenoviru	ses, Curr. T	op. Microb	iol. Imm	unol.,
	enhances		ted gene de	s to transferrin-polylivery and expression 92).				atl.
EXAMINER				DATE CONSIDERE	<u> </u>			
				on is in conformance by of this form with n				

Sheet 9 of 9 **Docket Number (Optional) Application Number** Form PTO-1449 4123US 09/348,354 INFORMATION DISCLOSURE/CITATION Applicant Havenga et al. IN AN APPLICATION JAN 2 6 2001 (Use several sheets if necess Filing Date July 7, 1999 Group Art Unit 1633 U.S. ADAMENTS DOCUMENTS **EXAMINER** DOCUMENT FILING DATE DATE CLASS SUBCLASS NAME IF APPROPRIATE INITIAL NUMBER 03/24/1998 5,731,190 Wickham et al. 5,756,086 05/26/1998 McClelland et al. 5,770,442 06/23/1998 Wickham et al. 5,922,315 07/13/1999 Roy **FOREIGN PATENT DOCUMENTS** Translation DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS YES NO WO 98/32842 07/30/1998 **PCT** WO 98/40509 09/17/1998 PCT **OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.) Watson et al., An Antigenic Analysis of the Adenovirus Type 2 Fibre Polypeptide, Journal of Virology, 69, 525-535 (1988). Wickham et al., Integrins $\alpha_{\nu}\beta_{3}$ and $\alpha_{\nu}\beta_{5}$ Promote Adenovirus Internalization but Not Virus Attachment, Cell, 73, 309-319 (1993). Wickham et al., Integrin ανβ5 Selectively Promotes Adenovirus Mediated Cell Membrane Permeabilization, Journal of Cell Biology, 127(1), 257-264 (1994). Chu et al., Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins, Gene Therapy, 1, 292-299 (1994). DATE CONSIDERED **EXAMINER**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.